Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
1600
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Small Cell Lung Cancer
Interventions
BIOLOGICAL:
Ivonescimab Injection
BIOLOGICAL:
Pembrolizumab Injection
Sponsor
Summit Therapeutics